Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Conatumumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Conatumumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Conatumumab. |
| Estrone | Estrone may increase the thrombogenic activities of Conatumumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Conatumumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Conatumumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Conatumumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Conatumumab. |
| Estriol | Estriol may increase the thrombogenic activities of Conatumumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Conatumumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Conatumumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Conatumumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Conatumumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Conatumumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Conatumumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Conatumumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Conatumumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Conatumumab. |
| Equol | Equol may increase the thrombogenic activities of Conatumumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Conatumumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Conatumumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Conatumumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Conatumumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Conatumumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Conatumumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Conatumumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Conatumumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Conatumumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Conatumumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Conatumumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Conatumumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Conatumumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Conatumumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Conatumumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Conatumumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Conatumumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Conatumumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Conatumumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Conatumumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Conatumumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Conatumumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Conatumumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Conatumumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Conatumumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Conatumumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Conatumumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Conatumumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Conatumumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Conatumumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Conatumumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Conatumumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Conatumumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Conatumumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Conatumumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Conatumumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Conatumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Conatumumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Conatumumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Conatumumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Conatumumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Conatumumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Conatumumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Conatumumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Conatumumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Conatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Conatumumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Conatumumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Conatumumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Conatumumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Conatumumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Conatumumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Conatumumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Conatumumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Conatumumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Conatumumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Conatumumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Conatumumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Conatumumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Conatumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Conatumumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Conatumumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Conatumumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Conatumumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Conatumumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Conatumumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Conatumumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Conatumumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Conatumumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Conatumumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Conatumumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Conatumumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Conatumumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Conatumumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Conatumumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Conatumumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Conatumumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Conatumumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Conatumumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Conatumumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Conatumumab. |